STE on NYSE

Steris

Logo: Steris, Public domain, via Wikimedia Commons4

Irish registered American medical device company

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

$5.9BRevenue, fiscal 20265
$782.3MNet income, fiscal 20265
1985Founded1

Compare with Edwards Lifesciences, Smith & Nephew or Zimmer Biomet Holdings, or pick any stock.

  • TickerSTE on NYSE1
  • Industryhealth care industry1
  • HeadquartersIreland1
  • Websitewww.steris.com
  • Legal formprivate company limited by shares, public limited company1
  • Incorporated inIreland6
  • Business address70 Sir John Rogerson'S Quay, Dublin, L2 26
  • Filer categoryLarge accelerated filer6

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

44.2%Gross margin5
18.6%Operating margin5
13.2%Net margin5
8.7%Revenue growth, 20265
10.9%Return on equity5
0.25×Debt to equity5
$972.4MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 52% of the revenue Steris broke down this way in fiscal 2026.

  1. Product$3.1B552%up 7% from 2025
  2. Service$2.9B548%up 11% from 2025
Products and services by year
Products and services202420252026
Product$2.8B$2.9B$3.1B
Service$2.4B$2.6B$2.9B

Business segments

Healthcare brought in 71% of the revenue Steris broke down this way in fiscal 2026.

  1. Healthcare$4.2B571%up 9% from 2025
  2. Applied Sterilization Technologies$1.1B519%up 10% from 2025
  3. Life Science$588.8M510%up 9% from 2025
Business segments by year
Business segments202420252026
Healthcare$3.6B$3.9B$4.2B
Applied Sterilization Technologies$954.0M$1.0B$1.1B
Life Science$571.7M$542.3M$588.8M

Regions

United States brought in 73% of the revenue Steris broke down this way in fiscal 2026.

  1. United States$4.3B573%up 8% from 2025
  2. Other foreign locations$1.5B525%up 11% from 2025
  3. Ireland$108.5M52%up 1% from 2025
Regions by year
Regions202420252026
United States$3.8B$4.0B$4.3B
Other foreign locations$1.3B$1.3B$1.5B
Ireland$82.7M$107.3M$108.5M

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue56¢$3.3B
  • Research and development2¢$112.9M
  • Selling, general and admin24¢$1.4B
  • Other costs1¢$61.4M
  • Income tax4¢$262.2M
  • Profit13¢$782.3M

Out of $5.9B in revenue.5

Where each dollar of operating cash went, fiscal 2026

  • Capital spending28¢$369.0M
  • Dividends paid18¢$241.8M
  • Share buybacks18¢$235.5M
  • Kept or used elsewhere37¢$495.1M

Out of $1.3B of cash from operations.5

Financial statements

Revenue891011125$5.9B in 2026+113% since 2019
0$2.0B$4.0B$6.0B2019: $2.8B$2.8B20192020: $3.0B$3.0B2020+9%2021: $3.1B$3.1B2021+3%2022: $4.2B$4.2B2022+36%2023: $4.5B$4.5B2023+7%2024: $5.1B$5.1B2024+13%2025: $5.5B$5.5B2025+6%2026: $5.9B$5.9B2026+9%
Gross profit891011125$2.6B in 2026+124% since 2019
0$1.0B$2.0B$3.0B2019: $1.2B$1.2B20192020: $1.3B$1.3B2020+12%2021: $1.3B$1.3B2021+2%2022: $1.9B$1.9B2022+40%2023: $2.0B$2.0B2023+5%2024: $2.2B$2.2B2024+12%2025: $2.4B$2.4B2025+8%2026: $2.6B$2.6B2026+9%
Operating income891011125$1.1B in 2026+168% since 2019
0$500.0M$1.0B$1.5B2019: $411.0M$411.0M20192020: $537.0M$537.0M2020+31%2021: $548.4M$548.4M2021+2%2022: $477.8M$477.8M2022−13%2023: $791.1M$791.1M2023+66%2024: $836.1M$836.1M2024+6%2025: $866.6M$866.6M2025+4%2026: $1.1B$1.1B2026+27%
Net income891011125$782.3M in 2026+158% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $303.7M$303.7M20192020: $407.7M$407.7M2020+34%2021: $397.4M$397.4M2021−3%2022: $243.9M$243.9M2022−39%2023: $107.0M$107.0M2023−56%2024: $378.2M$378.2M2024+253%2025: $614.6M$614.6M2025+63%2026: $782.3M$782.3M2026+27%

Every line of the income statement in the latest annual report, as filed.5

Period ending2026-03-312025-03-312024-03-31
Total revenues$5.9B$5.5B$5.1B
Cost of revenues$3.3B$3.1B$2.9B
Gross Profit$2.6B$2.4B$2.2B
Selling, general, and administrative$1.4B$1.3B$1.3B
Research and development$112.9M$107.6M$103.7M
Litigation Settlement, Loss$0$48.2M$0
Restructuring Costs$4.1M$46.0M$26.0M
Total operating expenses$1.5B$1.5B$1.4B
Income (loss) from operations$1.1B$866.6M$836.1M
Interest expense$60.7M$86.3M$144.4M
Interest income and miscellaneous expense-$9.8M-$8.4M-$11.0M
Other expense (income), net-$3.5M$7.4M$0
Total non-operating expenses, net$54.4M$70.4M$133.3M
Income (loss) before income tax expense (benefit)$1.0B$796.2M$702.8M
Income tax expense (benefit)$262.2M$184.7M$149.5M
Income from continuing operations, net of income tax$785.1M$611.6M$553.3M
Income (loss) from discontinued operations, net of income tax$0$4.5M-$173.2M
Net income$785.1M$616.1M$380.1M
Less: Net income attributable to noncontrolling interests$2.8M$1.4M$1.8M
Net income attributable to shareholders$782.3M$614.6M$378.2M
Income (Loss) from Continuing Operations, Per Basic Share$8$6$6
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share$0$0-$2
Earnings Per Share, Basic$7.97$6.24$3.83
Income (Loss) from Continuing Operations, Per Diluted Share$8$6$6
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share$0$0-$2
Earnings Per Share, Diluted$7.93$6.20$3.81
Cash dividends declared per common share outstanding$2.46$2.23$2.03

Compare Steris with another company

The story

Steris was founded in August 1985 in Ohio, under the name "Innovative Medical Technologies".

In 2012, Steris acquired US Endoscopy for $270 million. Steris also acquired Spectrum Surgical Instruments Corp. and Total Repair Express for $110 million combined.

On April 1, 2014, Steris announced its acquisition of Integrated Medical Systems International Inc. for ~$175 million, although it would only cost the company ~$140 million after tax benefits. Shortly after, Steris also acquired Chesterfield, Missouri-based Life Systems.

In October 2014, Steris executed a tax inversion from the United States to the United Kingdom, via an offer made to acquire UK-based Synergy Health for $1.9 billion. The tax inversion was notable as it was the first US inversion post the new rules introduced by the Obama administration in 2014 to curb US corporations moving their "legal domicile" to reduce their exposure to US corporate taxation.

On June 24, 2015, Steris announced the acquisitions of General Econopak for $175 million and Black Diamond Video for $51 million.

Steris filed accounts which showed global revenues of over US$2.6 billion in 2018, of which US$1.8 billion (or 70 percent) came from the US healthcare system; and employed ~12,000 people.

In November 2018, Steris announced that it would further re-domicile its legal headquarters from the United Kingdom to Ireland; Steris had reduced its corporate tax rate from 31.3 percent to 20 percent as a result of its 2014 tax inversion to the United Kingdom, however, it believed a further reduction could be achieved by moving to Ireland.

In April 2020, Steris received emergency use authorization from the FDA for a N95 mask sterilization system to help address the shortage of personal protective equipment during the 2019-20 coronavirus pandemic.

Read the full text

In November 2020, Steris acquired Key Surgical, a leading global provider of sterile processing, operating room, and endoscopy products.

In June 2021, Steris acquired Cantel Medical Corporation a provider of infection prevention products and services to endoscopy, dental and dialysis.

From Wikipedia’s article on Steris, shared under CC BY-SA 4.0.7

Leadership

Who has led Steris, and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. M. Lauren Brlas2000–2006
1990200020102020

Subsidiaries and ownership

Subsidiaries

  • Steris (France)
  • Steris (United Kingdom)

From Wikidata.1

Former names

  • STERIS LtdNov 6, 2018 to Mar 28, 20196

Timeline

  1. Jun 1, 1992Went public Listed on NYSE1
  2. 1985Founded Founded1

Recent filings

  1. Oct 13, 20268-K
  2. Oct 5, 20264
  3. Aug 18, 2026144
  4. Aug 12, 2026144
  5. Aug 12, 20264
  6. Aug 12, 20264
  7. Aug 12, 20264
  8. Aug 12, 20264
  9. Aug 12, 20264
  10. Aug 12, 20264
  11. Aug 12, 20264
  12. Aug 12, 20264
  13. Aug 7, 202610-Q
  14. Aug 6, 20268-K/A
  15. Aug 6, 20268-K

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2